<p>礼来公司（NYSE:LLY - 获取免费报告）在周一发布的报告中，BMO 资本市场的研究分析师将其目标价格从 840.00 美元上调至 930.00 美元。该券商目前对该股票给予 “跑赢大盘” 的评级。BMO 资本市场的目标价格指向该股票从前一交易日收盘价的潜在上涨幅度为 15.74%。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>诺和诺德的 Akero Therapeutics 收购目标礼来的领先产品</li>
</ul>
<p>其他几位研究分析师最近也对该股票发布了报告。摩根士丹利在 10 月 3 日的报告中将礼来公司的股票目标价格从 1,028.00 美元下调至 1,023.00 美元，并对该公司设定了 “增持” 评级。德意志银行将礼来公司的目标价格从 1,010.00 美元下调至 900.00 美元，并在 8 月 11 日的报告中对该股票给予 “买入” 评级。汇丰银行在 10 月 1 日的研究报告中将礼来公司的目标价格从 700.00 美元上调至 800.00 美元。汇丰全球研究在 8 月 27 日的研究报告中将礼来公司的评级从 “适度卖出” 上调至 “持有”。最后，Leerink Partners 在 8 月 7 日的研究报告中重申了 “市场表现” 评级，并对礼来公司的股票设定了 715.00 美元的目标价格。一位研究分析师对该股票给予了强烈买入评级，十五位分析师给予了买入评级，九位分析师给予了持有评级。根据 MarketBeat.com 的数据，礼来公司的共识评级为 “适度买入”，共识目标价格为 938.61 美元。</p>
<p><strong>查看我们最新的 LLY 股票报告</strong></p>
<h2>礼来公司股票表现</h2>
<ul>
<li>MarketBeat 周回顾 – 10/06 - 10/10</li>
</ul>
<p>礼来公司的股票在周一开盘价为 803.53 美元。该股票的市值为 7605.1 亿美元，市盈率为 52.52，市盈增长比率为 1.15，贝塔值为 0.47。该公司的速动比率为 1.00，流动比率为 1.28，债务股本比率为 1.86。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 935.63 美元。该公司的 50 日移动平均价格为 753.09 美元，200 日移动平均价格为 765.70 美元。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最后一次发布季度财报是在 8 月 7 日。该公司报告每股收益为 6.31 美元，超出分析师的共识预期 5.59 美元，超出幅度为 0.72 美元。该公司季度收入为 155.6 亿美元，而共识预期为 144.0 亿美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。该公司的季度收入较去年同期增长了 37.6%。去年同期，该公司每股收益为 3.92 美元。礼来公司已将其 2025 财年的指导目标设定为 21.750-23.000 美元每股收益。整体来看，分析师预计礼来公司在当前财年将发布 23.48 美元的每股收益。</p>
<h2>内部人士下注</h2>
<ul>
<li>5 个医疗保健股票推动该行业的大反弹</li>
</ul>
<p>在其他新闻中，董事 Gabrielle Sulzberger 在 8 月 12 日的交易中购买了 117 股该公司的股票。每股的平均购买价格为 641.18 美元，总价值为 75,018.06 美元。交易完成后，该董事持有该公司 2,703 股股票，价值 1,733,109.54 美元。此次交易使其持股增加了 4.52%。该购买在提交给证券交易委员会的文件中披露，文件可在 SEC 网站上找到。此外，董事 J Erik Fyrwald 在 8 月 12 日的交易中购买了 1,565 股该公司的股票。每股的平均购买成本为 642.33 美元，总交易额为 1,005,246.45 美元。交易完成后，该董事直接持有 74,578 股该公司股票，价值 47,903,686.74 美元。此次交易使其持股增加了 2.14%。该购买的披露信息可以在此找到。内部人士在上个季度购买了 4,514 股公司股票，价值 2,894,841 美元。公司内部人士持有公司股票的 0.14%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近买卖了该股票的股份。Brighton Jones LLC 在第四季度将其在礼来公司的股份增加了 22.0%。Brighton Jones LLC 现在拥有 9,597 股该公司的股票，价值 7,409,000 美元，此前在上个季度购买了 1,730 股。Revolve Wealth Partners LLC 在第四季度将其在礼来公司的股份增加了 2.8%。Revolve Wealth Partners LLC 现在拥有 1,471 股该公司的股票，价值 1,136,000 美元，此前在该期间购买了 40 股。Covestor Ltd 在第一季度将其在礼来公司的持股增加了 24.9%。Covestor Ltd 现在拥有 426 股该公司的股票，价值 352,000 美元，此前在上个季度购买了 85 股。GAMMA Investing LLC 在第一季度将其在礼来公司的股份增加了 25.8%。GAMMA Investing LLC 现在拥有 18,000 股该公司的股票，价值 14,866,000 美元，此前在该期间购买了 3,696 股。最后，MinichMacGregor Wealth Management LLC 在第一季度将其在礼来公司的股份增加了 1,164.9%。MinichMacGregor Wealth Management LLC 现在拥有 11,574 股该公司的股票，价值 9,559,000 美元，此前在该期间购买了 10,659 股。82.53% 的股票由机构投资者持有。</p>
<h2>关于礼来公司</h2>
<p>（获取免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原蛋白、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>3 只可以帮助抵御通货膨胀的食品杂货股票</li>
<li>为什么 SLB 可能是现在最聪明的石油股票</li>
<li>天然气价格持续上涨，这些股票应该受益</li>
<li>Waymo 的全球扩张增强了对 GOOGL 股票的看法</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并不能说明全部情况</li>
<li>全球医疗：这只 REIT 刚刚获得 30% 的目标价格</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在你考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>BMO 资本市场已将礼来的目标股价从 840.00 美元上调至 930.00 美元，维持 “跑赢大盘” 的评级。这个新目标暗示该股票相较于之前的收盘价有 15.74% 的潜在上涨空间。其他分析师也调整了他们的目标股价，普遍评级为 “适度买入”，平均目标价为 938.61 美元。礼来的股票开盘价为 803.53 美元，市值为 7605.1 亿美元，最近的季度财报显示出强劲的表现</p>

<p>Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective raised by research analysts at BMO Capital Markets from $840.00 to $930.00 in a report released on Monday,Briefing.com Automated Import reports. The brokerage presently has an &#34;outperform&#34; rating on the stock. BMO Capital Markets' target price points to a potential upside of 15.74% from the stock's previous close.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）在周一发布的报告中，BMO 资本市场的研究分析师将其目标价格从 840.00 美元上调至 930.00 美元。该券商目前对该股票给予 “跑赢大盘” 的评级。BMO 资本市场的目标价格指向该股票从前一交易日收盘价的潜在上涨幅度为 15.74%。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德的 Akero Therapeutics 收购目标礼来的领先产品</li>
</ul>
</div><p>Several other research analysts also recently issued reports on the stock. Morgan Stanley lowered their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an &#34;overweight&#34; rating for the company in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, August 11th. HSBC lifted their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Hsbc Global Res raised shares of Eli Lilly and Company from a &#34;moderate sell&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, August 27th. Finally, Leerink Partners reissued a &#34;market perform&#34; rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $938.61.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对该股票发布了报告。摩根士丹利在 10 月 3 日的报告中将礼来公司的股票目标价格从 1,028.00 美元下调至 1,023.00 美元，并对该公司设定了 “增持” 评级。德意志银行将礼来公司的目标价格从 1,010.00 美元下调至 900.00 美元，并在 8 月 11 日的报告中对该股票给予 “买入” 评级。汇丰银行在 10 月 1 日的研究报告中将礼来公司的目标价格从 700.00 美元上调至 800.00 美元。汇丰全球研究在 8 月 27 日的研究报告中将礼来公司的评级从 “适度卖出” 上调至 “持有”。最后，Leerink Partners 在 8 月 7 日的研究报告中重申了 “市场表现” 评级，并对礼来公司的股票设定了 715.00 美元的目标价格。一位研究分析师对该股票给予了强烈买入评级，十五位分析师给予了买入评级，九位分析师给予了持有评级。根据 MarketBeat.com 的数据，礼来公司的共识评级为 “适度买入”，共识目标价格为 938.61 美元。</p>
</div><p><strong>View Our Latest Stock Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LLY 股票报告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 10/06 - 10/10</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 10/06 - 10/10</li>
</ul>
</div><p>Eli Lilly and Company stock opened at $803.53 on Monday. The stock has a market cap of $760.51 billion, a PE ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The business's 50-day moving average price is $753.09 and its two-hundred day moving average price is $765.70.</p>
<div class="lb-trans"><p>礼来公司的股票在周一开盘价为 803.53 美元。该股票的市值为 7605.1 亿美元，市盈率为 52.52，市盈增长比率为 1.15，贝塔值为 0.47。该公司的速动比率为 1.00，流动比率为 1.28，债务股本比率为 1.86。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 935.63 美元。该公司的 50 日移动平均价格为 753.09 美元，200 日移动平均价格为 765.70 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最后一次发布季度财报是在 8 月 7 日。该公司报告每股收益为 6.31 美元，超出分析师的共识预期 5.59 美元，超出幅度为 0.72 美元。该公司季度收入为 155.6 亿美元，而共识预期为 144.0 亿美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。该公司的季度收入较去年同期增长了 37.6%。去年同期，该公司每股收益为 3.92 美元。礼来公司已将其 2025 财年的指导目标设定为 21.750-23.000 美元每股收益。整体来看，分析师预计礼来公司在当前财年将发布 23.48 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健股票推动该行业的大反弹</li>
</ul>
</div><p>In other news, Director Gabrielle Sulzberger purchased 117 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 over the last quarter. Company insiders own 0.14% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Gabrielle Sulzberger 在 8 月 12 日的交易中购买了 117 股该公司的股票。每股的平均购买价格为 641.18 美元，总价值为 75,018.06 美元。交易完成后，该董事持有该公司 2,703 股股票，价值 1,733,109.54 美元。此次交易使其持股增加了 4.52%。该购买在提交给证券交易委员会的文件中披露，文件可在 SEC 网站上找到。此外，董事 J Erik Fyrwald 在 8 月 12 日的交易中购买了 1,565 股该公司的股票。每股的平均购买成本为 642.33 美元，总交易额为 1,005,246.45 美元。交易完成后，该董事直接持有 74,578 股该公司股票，价值 47,903,686.74 美元。此次交易使其持股增加了 2.14%。该购买的披露信息可以在此找到。内部人士在上个季度购买了 4,514 股公司股票，价值 2,894,841 美元。公司内部人士持有公司股票的 0.14%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd boosted its holdings in Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company's stock worth $352,000 after acquiring an additional 85 shares in the last quarter. GAMMA Investing LLC grew its stake in Eli Lilly and Company by 25.8% in the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock valued at $14,866,000 after acquiring an additional 3,696 shares during the period. Finally, MinichMacGregor Wealth Management LLC raised its position in shares of Eli Lilly and Company by 1,164.9% during the first quarter. MinichMacGregor Wealth Management LLC now owns 11,574 shares of the company's stock worth $9,559,000 after purchasing an additional 10,659 shares during the period. 82.53% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该股票的股份。Brighton Jones LLC 在第四季度将其在礼来公司的股份增加了 22.0%。Brighton Jones LLC 现在拥有 9,597 股该公司的股票，价值 7,409,000 美元，此前在上个季度购买了 1,730 股。Revolve Wealth Partners LLC 在第四季度将其在礼来公司的股份增加了 2.8%。Revolve Wealth Partners LLC 现在拥有 1,471 股该公司的股票，价值 1,136,000 美元，此前在该期间购买了 40 股。Covestor Ltd 在第一季度将其在礼来公司的持股增加了 24.9%。Covestor Ltd 现在拥有 426 股该公司的股票，价值 352,000 美元，此前在上个季度购买了 85 股。GAMMA Investing LLC 在第一季度将其在礼来公司的股份增加了 25.8%。GAMMA Investing LLC 现在拥有 18,000 股该公司的股票，价值 14,866,000 美元，此前在该期间购买了 3,696 股。最后，MinichMacGregor Wealth Management LLC 在第一季度将其在礼来公司的股份增加了 1,164.9%。MinichMacGregor Wealth Management LLC 现在拥有 11,574 股该公司的股票，价值 9,559,000 美元，此前在该期间购买了 10,659 股。82.53% 的股票由机构投资者持有。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原蛋白、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Why SLB Could Be the Smartest Oil Stock to Buy Now</li>
<li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li>
<li>Waymo’s Global Expansion Strengthens the Case for GOOGL Stock</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>Global Medical: This REIT Just Got a 30% Price Target</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>3 只可以帮助抵御通货膨胀的食品杂货股票</li>
<li>为什么 SLB 可能是现在最聪明的石油股票</li>
<li>天然气价格持续上涨，这些股票应该受益</li>
<li>Waymo 的全球扩张增强了对 GOOGL 股票的看法</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并不能说明全部情况</li>
<li>全球医疗：这只 REIT 刚刚获得 30% 的目标价格</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BMO 资本市场将礼来公司（NYSE:LLY）的目标股价上调至 930.00 美元